Ollin Biosciences closed an oversubscribed $330 million Series B to fund global Phase 3 development of OLN324.
- Amount
- $330M
- Stage
- Series B
- Announced
- 24 June 2026
- Leads
- TCGX, ARCH Venture Partners
- Other investors
- a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., Mubadala Capital, Monograph Capital
- Use of funds
- Global Phase 3 development of OLN324 in DME and wet AMD, and advancing OLN
- Checked
- Amount and date checked against the press source